266 related articles for article (PubMed ID: 19707201)
1. Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas.
Martinho O; Longatto-Filho A; Lambros MB; Martins A; Pinheiro C; Silva A; Pardal F; Amorim J; Mackay A; Milanezi F; Tamber N; Fenwick K; Ashworth A; Reis-Filho JS; Lopes JM; Reis RM
Br J Cancer; 2009 Sep; 101(6):973-82. PubMed ID: 19707201
[TBL] [Abstract][Full Text] [Related]
2. Prevalence, clinico-pathological value, and co-occurrence of PDGFRA abnormalities in diffuse gliomas.
Alentorn A; Marie Y; Carpentier C; Boisselier B; Giry M; Labussière M; Mokhtari K; Hoang-Xuan K; Sanson M; Delattre JY; Idbaih A
Neuro Oncol; 2012 Nov; 14(11):1393-403. PubMed ID: 23074200
[TBL] [Abstract][Full Text] [Related]
3. Platelet-derived growth factor may be a potential diagnostic and prognostic marker for cholangiocarcinoma.
Boonjaraspinyo S; Boonmars T; Wu Z; Loilome W; Sithithaworn P; Nagano I; Pinlaor S; Yongvanit P; Nielsen PS; Pairojkul C; Khuntikeo N
Tumour Biol; 2012 Oct; 33(5):1785-802. PubMed ID: 22733151
[TBL] [Abstract][Full Text] [Related]
4. Silent mutations in KIT and PDGFRA and coexpression of receptors with SCF and PDGFA in Merkel cell carcinoma: implications for tyrosine kinase-based tumorigenesis.
Kartha RV; Sundram UN
Mod Pathol; 2008 Feb; 21(2):96-104. PubMed ID: 18084259
[TBL] [Abstract][Full Text] [Related]
5. Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas.
Paugh BS; Zhu X; Qu C; Endersby R; Diaz AK; Zhang J; Bax DA; Carvalho D; Reis RM; Onar-Thomas A; Broniscer A; Wetmore C; Zhang J; Jones C; Ellison DW; Baker SJ
Cancer Res; 2013 Oct; 73(20):6219-29. PubMed ID: 23970477
[TBL] [Abstract][Full Text] [Related]
6. Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas.
Puputti M; Tynninen O; Sihto H; Blom T; Mäenpää H; Isola J; Paetau A; Joensuu H; Nupponen NN
Mol Cancer Res; 2006 Dec; 4(12):927-34. PubMed ID: 17189383
[TBL] [Abstract][Full Text] [Related]
7. Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma.
Koschmann C; Zamler D; MacKay A; Robinson D; Wu YM; Doherty R; Marini B; Tran D; Garton H; Muraszko K; Robertson P; Leonard M; Zhao L; Bixby D; Peterson L; Camelo-Piragua S; Jones C; Mody R; Lowenstein PR; Castro MG
Oncotarget; 2016 Oct; 7(40):65696-65706. PubMed ID: 27582545
[TBL] [Abstract][Full Text] [Related]
8. miR-34a repression in proneural malignant gliomas upregulates expression of its target PDGFRA and promotes tumorigenesis.
Silber J; Jacobsen A; Ozawa T; Harinath G; Pedraza A; Sander C; Holland EC; Huse JT
PLoS One; 2012; 7(3):e33844. PubMed ID: 22479456
[TBL] [Abstract][Full Text] [Related]
9. Amplification of the platelet-derived growth factor receptor-A (PDGFRA) gene occurs in oligodendrogliomas with grade IV anaplastic features.
Smith JS; Wang XY; Qian J; Hosek SM; Scheithauer BW; Jenkins RB; James CD
J Neuropathol Exp Neurol; 2000 Jun; 59(6):495-503. PubMed ID: 10850862
[TBL] [Abstract][Full Text] [Related]
10. Better prognosis of patients with glioma expressing FGF2-dependent PDGFRA irrespective of morphological diagnosis.
Chen D; Persson A; Sun Y; Salford LG; Nord DG; Englund E; Jiang T; Fan X
PLoS One; 2013; 8(4):e61556. PubMed ID: 23630597
[TBL] [Abstract][Full Text] [Related]
11. EPHA2 mediates PDGFA activity and functions together with PDGFRA as prognostic marker and therapeutic target in glioblastoma.
Gai QJ; Fu Z; He J; Mao M; Yao XX; Qin Y; Lan X; Zhang L; Miao JY; Wang YX; Zhu J; Yang FC; Lu HM; Yan ZX; Chen FL; Shi Y; Ping YF; Cui YH; Zhang X; Liu X; Yao XH; Lv SQ; Bian XW; Wang Y
Signal Transduct Target Ther; 2022 Feb; 7(1):33. PubMed ID: 35105853
[TBL] [Abstract][Full Text] [Related]
12. Homozygous loss of ADAM3A revealed by genome-wide analysis of pediatric high-grade glioma and diffuse intrinsic pontine gliomas.
Barrow J; Adamowicz-Brice M; Cartmill M; MacArthur D; Lowe J; Robson K; Brundler MA; Walker DA; Coyle B; Grundy R
Neuro Oncol; 2011 Feb; 13(2):212-22. PubMed ID: 21138945
[TBL] [Abstract][Full Text] [Related]
13. PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma.
Phillips JJ; Aranda D; Ellison DW; Judkins AR; Croul SE; Brat DJ; Ligon KL; Horbinski C; Venneti S; Zadeh G; Santi M; Zhou S; Appin CL; Sioletic S; Sullivan LM; Martinez-Lage M; Robinson AE; Yong WH; Cloughesy T; Lai A; Phillips HS; Marshall R; Mueller S; Haas-Kogan DA; Molinaro AM; Perry A
Brain Pathol; 2013 Sep; 23(5):565-73. PubMed ID: 23438035
[TBL] [Abstract][Full Text] [Related]
14. Molecular alterations of KIT oncogene in gliomas.
Gomes AL; Reis-Filho JS; Lopes JM; Martinho O; Lambros MB; Martins A; Schmitt F; Pardal F; Reis RM
Cell Oncol; 2007; 29(5):399-408. PubMed ID: 17726262
[TBL] [Abstract][Full Text] [Related]
15. PDGFRA gain in low-grade diffuse gliomas.
Motomura K; Mittelbronn M; Paulus W; Brokinkel B; Keyvani K; Sure U; Wrede K; Nakazato Y; Tanaka Y; Nonoguchi N; Pierscianek D; Kim YH; Mariani L; Vital A; Perry A; Ohgaki H
J Neuropathol Exp Neurol; 2013 Jan; 72(1):61-6. PubMed ID: 23242283
[TBL] [Abstract][Full Text] [Related]
16. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease.
Paugh BS; Qu C; Jones C; Liu Z; Adamowicz-Brice M; Zhang J; Bax DA; Coyle B; Barrow J; Hargrave D; Lowe J; Gajjar A; Zhao W; Broniscer A; Ellison DW; Grundy RG; Baker SJ
J Clin Oncol; 2010 Jun; 28(18):3061-8. PubMed ID: 20479398
[TBL] [Abstract][Full Text] [Related]
17. Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas.
Tamborini E; Miselli F; Negri T; Lagonigro MS; Staurengo S; Dagrada GP; Stacchiotti S; Pastore E; Gronchi A; Perrone F; Carbone A; Pierotti MA; Casali PG; Pilotti S
Clin Cancer Res; 2006 Dec; 12(23):6920-8. PubMed ID: 17145809
[TBL] [Abstract][Full Text] [Related]
18. Amplification and overexpression of KIT, PDGFRA, and VEGFR2 in medulloblastomas and primitive neuroectodermal tumors.
Blom T; Roselli A; Häyry V; Tynninen O; Wartiovaara K; Korja M; Nordfors K; Haapasalo H; Nupponen NN
J Neurooncol; 2010 Apr; 97(2):217-24. PubMed ID: 19779861
[TBL] [Abstract][Full Text] [Related]
19. IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations.
Yang RR; Shi ZF; Zhang ZY; Chan AK; Aibaidula A; Wang WW; Kwan JSH; Poon WS; Chen H; Li WC; Chung NY; Punchhi G; Chu WC; Chan IS; Liu XZ; Mao Y; Li KK; Ng HK
Brain Pathol; 2020 May; 30(3):541-553. PubMed ID: 31733156
[TBL] [Abstract][Full Text] [Related]
20. Distinct phenotypic differences associated with differential amplification of receptor tyrosine kinase genes at 4q12 in glioblastoma.
Burford A; Little SE; Jury A; Popov S; Laxton R; Doey L; Al-Sarraj S; Jürgensmeier JM; Jones C
PLoS One; 2013; 8(8):e71777. PubMed ID: 23990986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
